Roche acquired Genentech in 2009 for nearly US$47 billion. Although the deal sparked concerns that Genentech's free-wheeling science-based culture was at risk, Roche always said it wanted to maintain the biotech's independence. Richard Scheller, the former Chief Scientific Officer of the stand-alone Genentech and Head of Genentech Research and Early Development (gRED) under Roche, has recently retired, and this changing of the guard has stirred the old concerns. Now Mike Varney, former Head of Small Molecules at Genentech, is stepping up to take the reins. The commitment to Genentech's culture of innovation remains unwavering, he tells Asher Mullard.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mike Varney. Nat Rev Drug Discov 14, 158–159 (2015). https://doi.org/10.1038/nrd4566
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4566
This article is cited by
-
Roche buys $1 billion majority stake in Foundation
Nature Reviews Drug Discovery (2015)
